Showing 4811-4820 of 5623 results for "".
- Iveric bio Announces First Patient Dosed in Second Zimura Phase 3 Trial for Treatment of GAhttps://modernod.com/news/iveric-bio-announces-first-patient-dosed-in-second-zimura-phase-3-trial-for-treatment-of-ga/2477951/Iveric bio announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (
- The Vision Council Raises $38,100 for Justice Initiativeshttps://modernod.com/news/the-vision-council-raises-38100-for-justice-initiatives/2477948/The Vision Council is pleased to announce that the organization’s “Open Your Eyes Frame Vendue” has raised $38,100 for the Equal Justice Initiative and My Brother’s Keeper Alliance. The week-long virtual auction featured frames with special significance, including one-of-a-kind or nev
- Envision Conference Goes Virtual This Augusthttps://modernod.com/news/envision-conference-goes-virtual-this-august/2477945/Envision has announced that it is shifting the format for Envision Conference East to a live-stream webinar occurring August 14-15, 2020. In addition to creating a safer environment in the midst of the COVID-19 crisis, the virtual format will facilitate participation in
- Novartis Withdraws Marketing Application of Dry Eye Drug Xiidra in Europehttps://modernod.com/news/novartis-pulls-eu-filing-seeking-approval-of-xiidra-for-dry-eye-disease/2477942/Novartis has decided to withdraw its marketing application seeking approval of dry eye drug Xiidra (lifitegrast) in Europe. The decision comes after the European Medicines Agency (EMA) said the drug’s benefits did not outweigh its risks. Novartis pulled the application on June 18 after the
- DORC Launches New Range of EVA EquiPhaco Needles and Sleeveshttps://modernod.com/news/dorc-launches-new-range-of-eva-equiphaco-needles-and-sleeves/2477940/DORC announced the launch of a new range of EVA EquiPhaco needles and sleeves, which are designed to deliver superior ultrasound efficiency, improved anterior chamber stability, and easier sleeve positioning. T
- 2021 ASCRS Annual Meeting Pushed Back to Augusthttps://modernod.com/news/2021-ascrs-annual-meeting-pushed-back-to-august/2477939/ASCRS announced that it is pushing back its 2021 annual meeting in San Francisco from April to August. “This decision was thoroughly researched and discussed, and when weighed against the risks of possibly losing another meeting to the coronavirus, we felt we had no other alternative
- The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/2477937/Citing an unfavorable benefit-risk ratio, the FDA rejected Allergan and co-developer Molecular Partners’ wet AMD drug candidate Abicipar pegol. The FDA issued a complete response letter to the biologics license application (BLA) for Abicipar pegol, a novel, investigational DARPin the
- Visual Clinic’s Patient Flow Management Solution Aims to Help Eye Care Clinics Operate Post-COVID-19https://modernod.com/news/visual-clinics-patient-flow-management-solution-aims-to-help-eye-care-clinics-operate-post-covid-19/2477935/Visual Clinic is offering a solution designed to help eye care clinics achieve better patient flow. The software aims to help practices run at peak efficiency, improve the patient experience, maximize practice resources, and keep overhead costs low while optimizing revenue. Additionally
- Saunders Finds Life After Allergan on Board at Newly IPO’ed BridgeBiohttps://modernod.com/news/saunders-finds-life-after-allergan-on-board-at-newly-ipoed-bridgebio/2477933/Less than 2 months after Allergan was officially taken in by AbbVie, its last helmsman, Brent Saunders, has landed on the board of a young biotech that recently pulled off a large IPO, according to a FiercePharma
- AsclepiX Therapeutics Announces $35 Million Series A Financinghttps://modernod.com/news/asclepix-therapeutics-announces-35-million-series-a-financing/2477929/AsclepiX Therapeutics announced that it has closed a $35 million Series A financing to fund phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (AMD) and macular edema secondary to r